title: Orphan drug designation for pracinostat, volasertib and alvocidib in AML.
authors.affiliation: Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
authors.forename: Prithviraj
authors.initials: P
authors.lastname: Bose
authors.affiliation: Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: stgrant@vcu.edu.
authors.forename: Steven
authors.initials: S
authors.lastname: Grant
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000145:classification* / Q000627:therapeutic use; D055808:Drug Discovery / Q000639:trends; D044127:Epigenesis, Genetic / Q000187:drug effects; D005419:Flavonoids / Q000145:classification* / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009965:Orphan Drug Production; D010880:Piperidines / Q000145:classification* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011621:Pteridines / Q000145:classification* / Q000627:therapeutic use; D009626:Terminology as Topic
chemical_list: D000970:Antineoplastic Agents; C541363:BI 6727; D001562:Benzimidazoles; D005419:Flavonoids; D056572:Histone Deacetylase Inhibitors; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011621:Pteridines; C557525:SB939 compound; C077990:alvocidib
keywords: AML; Alvocidib; Flavopiridol; Pracinostat; Rational combinations; Volasertib